MBX Biosciences, Inc.
MBX
$10.30
$0.131.28%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 57.83% | 57.38% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.65% | 93.13% | -- | -- | -- |
| Operating Income | -92.65% | -93.13% | -- | -- | -- |
| Income Before Tax | -88.61% | -90.17% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -88.61% | -90.17% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.61% | -90.17% | -- | -- | -- |
| EBIT | -92.65% | -93.13% | -- | -- | -- |
| EBITDA | -92.77% | -93.30% | -- | -- | -- |
| EPS Basic | 52.70% | 17.69% | -- | -- | -- |
| Normalized Basic EPS | 53.66% | 19.72% | -- | -- | -- |
| EPS Diluted | 52.70% | 17.69% | -- | -- | -- |
| Normalized Diluted EPS | 53.66% | 19.72% | -- | -- | -- |
| Average Basic Shares Outstanding | 1,587.69% | 940.15% | -- | -- | -- |
| Average Diluted Shares Outstanding | 1,587.69% | 940.15% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |